Retinal Disease

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, David S. Boyer, MD, of Retina-Vitreous Associates Medical Group in Los Angeles, discusses targeting mitochondria in retinal disease treatment.

Merck will acquire EyeBio through a subsidiary in an agreement potentially valued at $3 billion, according to a press release.

FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Carl D. Regillo, MD, discusses promising results for the Ixo-vec gene therapy for neovascular age-related macular degeneration.

FORT LAUDERDALE, Fla. — Social and political determinates of health must be addressed to provide all patients with better visual outcomes, according to a speaker at the Retina World Congress.

An intravitreal injection is now the most common surgical procedure performed in the United States by an ophthalmologist.

WAILEA, Hawaii — In this Healio Video Perspective from Retina 2024, David A. Eichenbaum, MD, discusses the potential for gene therapy to reduce the intravitreal injection treatment burden in retinal disease.

Among the newer diagnostics used to quantify diabetic retinal disease, the level of evidence is highest for spectral-domain OCT, suggesting its potential role in an updated classification scheme, according to a literature review.